S. Nayiager

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Michael Schiff, M. Keiserman, C. Codding et al. · Annals of the Rheumatic Diseases · 2007 · 536 citations · Full text

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

Joan M. Bathon, M. Robles, Antônio Carlos Ximenes et al. · Annals of the Rheumatic Diseases · 2011 · 78 citations · Full text

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study

Peter Nash, S. Nayiager, Mark C. Genovese et al. · Arthritis Care & Research · 2012 · 71 citations

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

Alan Kivitz, S. Nayiager, T. Schimansky et al. · Alimentary Pharmacology & Therapeutics · 2004 · 61 citations · Full text

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

Michael Schiff, M. Keiserman, C. Codding et al. · Annals of the Rheumatic Diseases · 2011 · 55 citations · Full text